Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 May 16

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.

View Paper

Abstract

What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.

Related Questions

At what PSA do you initiate ADT for a biochemical recurrence after prostate radiotherapy (adjuvant, salvage, or definitive)?

3 Answers

Mednet Member

Radiation Oncology · University of Pennsylvania

Great question, and one that highlights the variability in practice and philosophy that often emerges to fill the void when hard data and concrete guidelines are lacking. I find that the PSA doubling-time (DT) often tracks with patient and provider anxiety levels; a rapid DT (<8-10 mos or so) in an ...